DOI:
10.1055/s-00000068
Seminars in Interventional Radiology
LinksClose Window
References
Finn RS, Merle P, Granito A. et al.
Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial.
J Clin Oncol 2017;
35 (04) 344
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.